Table 1 Clinical characteristics in the two patient populations
time-point of semen analysis | before orchiectomy | after orchiectomy |
|---|---|---|
Age * | ||
eligible (n) | 163 | 242 |
< 30 years (n; %) | 71 (43.6%) | 144 (59.5%) |
30–39 years (n; %) | 81 (49.7%) | 85 (35.1%) |
> 40 years (n; %) | 11 (6.8%) | 13 (5.4%) |
Histology * | ||
eligible (n) | 163 | 241 |
Seminoma (n; %) | 92 (56.4%) | 81 (33.6%) |
Nonseminoma (n; %) | 71 (43.5%) | 160 (66.4%) |
Clinical stage * | ||
eligible (n) | 158 | 237 |
CS1 (n; %) | 128 (81.0%) | 130 (54.8%) |
CS2a,b (n; %) | 24 (15.2%) | 68 (28.7%) |
CS2c (n; %) | 3 (1.9%) | 9 (3.8%) |
CS3 (n; %) | 3 (1.9%) | 30 (12.7%) |
Tumour size | ||
eligible (n) | 156 | 191 |
< 2 cm (n; %) | 38 (24.4%) | 36 (18.8%) |
2.1–4 cm (n; %) | 83 (53.2%) | 105 (55.0%) |
> 4 cm (n; %) | 35 (22.4%) | 50 (26.2%) |
AFP- serum level | ||
eligible (n) | 159 | 196 |
< ULN | 125 (78.6%) | 131 (66.8%) |
1—10 × ULN | 19 (11.9%) | 37 (18.9%) |
11—50 × ULN | 12 (7.6%) | 18 (9.2%) |
> 50 × ULN | 3 (1.9%) | 10 (5.1%) |
beta HCG- serum level | ||
eligible (n) | 159 | 198 |
< ULN | 89 (55.9%) | 122 (61.6%) |
1—10 × ULN | 38 (23.9%) | 34 (17.2%) |
11—50 × ULN | 16 (10.1%) | 18 (9.1%) |
> 50 × ULN | 16 (10.1%) | 24 (12.1%) |